SCHEMBL4479914

SCHEMBL4479914

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)c(F)c3)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 12/20 0.63
EGFR P00533 6/20 0.63
KDR P35968 5/20 0.61
AXL P30530 4/20 0.58
KIT P10721 3/20 0.58
RET P07949 2/20 0.58
IGF1R P08069 2/20 0.58
SRC P12931 2/20 0.58
MST1R Q04912 2/20 0.58
FLT3 P36888 4/20 0.58
PDGFRA P16234 2/20 0.56
FGFR2 P21802 2/20 0.56
PLK4 O00444 1/20 0.55
STK25 O00506 1/20 0.55
CIT O14578 1/20 0.55
AURKA O14965 1/20 0.55
CHUK O15111 1/20 0.55
MUSK O15146 1/20 0.55
EPHB6 O15197 1/20 0.55
MAPK13 O15264 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4473428 0.99 MET (0.62) METEGFRKDRAXLKIT
SCHEMBL4469351 0.97 MET (0.59) METEGFRKDRAXLKIT
Hydrochloric Acid SCHEMBL4486090 0.96 MET (0.58) METEGFRKDRAXLKIT
SCHEMBL4478285 0.93 KDR (0.59) METEGFRKDRAXLKIT
SCHEMBL4471382 0.92 KDR (0.63) METEGFRKDRFGFR2FLT1
SCHEMBL4474426 0.91 KDR (0.59) METEGFRKDRAXLKIT
SCHEMBL4482167 0.90 KDR (0.58) METEGFRKDRAXLKIT
SCHEMBL4487973 0.90 KDR (0.61) METEGFRKDRFGFR2FLT1
SCHEMBL4468963 0.90 KDR (0.60) METEGFRKDRAXLKIT
SCHEMBL4489534 0.90 MET (0.68) METEGFRKDRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 MET 6/4885EGFR 16/4885KDR 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.